Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web.
La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias.
Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso.
En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web.
Más información en el apartado POLÍTICA DE COOKIES de nuestra página web.



Our medical oncologists and laboratory investigators are regular speakers and organizers of some of the most important international seminars and scientific meetings.

We have presented the results of our investigations into the causes of cancer and novel treatments at some of the most important national and international oncology congresses.


Annual Meeting, American Society of Clinical Oncology (ASCO)

DATE02/06/2017 - 06/06/2017


Alectinib vs. crizotinib  in ALK+ NSCLC (ALEX study)

Alice T. Shaw, Solange Peters, Tony Mok, Shirish M. Gadgeel, Jin Seok Ahn, Sai-Hong Ignatius Ou, Maurice Perol, Rafal Dziadziuszko, Dong-Wan Kim, Rafael Rosell, Ali Hassan Zeaiter, Ting Liu, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, D. Ross Camidge
[return] Dacomitinib vs. gefitinib in EGFR mutant NSCLC (ARCHER 1050)
Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, Rafael Rosell, Jesus Corral, Maria Rita Migliorino, Adam Pluzanski, Rolf Linke, Eric Sbar, Tao Wang, Yi-Long Wu

Phase 1/2 Study of Veliparib (V) Combined With Carboplatin (Cb) and Etoposide (E) in Patients (pts) With Extensive-stage Disease (ED) Small Cell Lung Cancer (SCLC) and Other Solid Tumors: Phase 1 Results
Florence Atrafi, Harry J. M. Groen, Lauren A. Byers, Elena Garralda, Martijn P. Lolkema, Randeep S. Sangha, Santiago Viteri, Young Kwang Chae, D. Ross Camidge, Nashat Y. Gabrail, Tina Waskiewicz, Beibei Hu, Tu Xu, Hao Xiong, Elizabeth Hoening, Philip Komarnitsky, Antonio Calles

Interferon-gamma, a marker of response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) and melanoma patients
Niki Karachaliou, Guillermo Crespo, Erika Aldeguer, Ana Drozdowsky, Ana Gimenez-Capitan, Cristina Teixidó, Miguel Angel Molina, Santiago Viteri, Daniela Morales, María de los Llanos Gil, María González Cao, Salvador Martín Algarra, Elisabeth Pérez-Ruiz, Iván Márquez-Rodas, Delvys Rodriguez-Abreu, Remei Blanco, Teresa Puértolas, María Angeles Royo, Rafael Rosell

HIV as a model for understanding immuno-oncology


PLACEAuditorium, Dexeus University Hospital

The objective of this meeting is to bring together scientists who share a common interest in immunotherapy with the aim of fostering new interdisciplinary approaches and inspiring scientists and clinicians. The workshop will provide a space for professionals from different disciplines to interact and share experiences, learn about the latest research findings, develop novel hypotheses, and enhance insights into how to modulate the immune response.

Cologne Conference on Lung Cancer


PLACECologne, Germany

Resistance to next-generation EGFR-inhibitors: consequences for clinical trial design Rosell R, MD, PhD

Overcoming resistance to targeted drugs: the clinical perspective Rosell R, MD, PhD

American Association for Cancer Research (AACR)

DATE01/04/2017 - 05/04/2017

PLACEWashington, USA

Routine Testing for KRAS mutations in cfDNA from blood of advanced cancer patients Garzón M, Mayo C, Jordana Ariza N, Balada i Bel A, García B, Villatoro S, Bertrán Alamillo J, Martínez Bueno A, Viteri Ramirez S, Pérez Rosado A, Morales Espinosa D, José Catalán M, Karachaliou N, Molina Vila M.A, Rosell R.



Analysis of EML4-ALK fusion transcripts in plasma and platelets to monitor response to crizotinib in EML4-ALK positive non-small cell lung cancer patients Aguado C, Teixidó C, Giménez-Capitán A, de los Llanos Gil M, Rodríguez S, Karachaliou N, Viteri S, Peg V, Aldeguer E, Alonso L, Rosell R, Molina-Vila M.A

Tumor cells with acquired resistance to EGFR inhibitors and overexpression or activation of AXL, MET and FGFR1 are insensitive to single-agent treatment targeting AXL, MET or FGFR Bertran-Alamillo J, Molina-Vila M.A, Teixidó C, Codony-Servat J, Giménez-Capitán J, Codony-Servat C, García-Román S, Aldeguer E, Rodríguez S, Rosell R

MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC)  are not associated with MET amplification and overexpression Giménez-Capitán A, Teixidó C, Rodríguez S, Aguado C, Bertran-Alamillo J, Castellví J, Yeste Z, Perez A, Rosell R, Molina-Vila M.A

Novel, non-invasive tools for lung cancer assessment

DATE20/03/2017 - 23/03/2017

PLACEDr. Rosell Oncology Institute

Course on the applications of exhaled breath condensate for lung cancer diagnostics given by Professor Giovanna Elisiana Carpagnano from the University of Foggia, Italy.